Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 6INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 2Carcinoma, Transitional Cell 2Keratosis, Actinic 1Glioma 1Glioblastoma 1Carcinoma, Basal Cell 1

Interventions

HhAntag691 11sonidegib 5cemiplimab 5methyl 5-aminolevulinate 4daromun 4Imiquimod 3IPI-926 3gusacitinib 2Photochemotherapy 2Drug Evaluation 23-ingenyl angelate 2tozuleristide 1silmitasertib 1pembrolizumab 1TAK-441 1NVP-LEQ506 1MAPRE1 protein, human 1Intravital Microscopy 1Interleukin-2 1Injections 1IFL protocol 1Folfox protocol 1Capecitabine 1Bevacizumab 1BO-112 1BMS-833923 1BF-200 ALA 1Ascorbic Acid 1Aminolevulinic Acid 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Basal Cell × 1-phenyl-3,3-dimethyltriazene × Clear all
NCT00472043 2024-08-06

PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma

Galderma R&D

Phase 3 Completed
66 enrolled 15 charts
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡